Pyxis Oncology, Inc.

Equities

PYXS

US7473241013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 02/07/2024 BST			5-day change	1st Jan Change
2.94 ^USD	-8.12%		-3.92%	+63.33%

06-10	Pyxis Oncology, Inc. Appoints Michael A. Metzger to Its Board of Directors	CI
05-14	Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 22, 2023 at 11:21 am

Pyxis Oncology, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 120.72 million compared to USD 75.98 million a year ago. Basic loss per share from continuing operations was USD 3.65 compared to USD 8.95 a year ago.

Latest news about Pyxis Oncology, Inc.

Pyxis Oncology, Inc. Appoints Michael A. Metzger to Its Board of Directors	06-10	CI
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M	05-14	MT
Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President	05-14	CI
H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating	03-22	MT
Health Care Up on Drug Sales Optimism -- Health Care Roundup	03-21	DJ
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of Directors	03-13	CI
Pyxis Oncology Announces Private Placement of Shares, Pre-Funded Warrants to Raise $50 Million	02-27	MT
Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors	02-25	CI
BTIG Initiates Pyxis Oncology With Buy Rating, $8 Price Target	02-09	MT
Leerink Partners Initiates Coverage on Pyxis Oncology with Outperform Rating, $12 Price Target	01-23	MT
HC Wainwright Starts Pyxis Oncology With Buy Rating, $4 Price Target	11-30	MT
Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer	11-28	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Pyxis Oncology Shares Fall After CEO Sells Stock	19/09/23	MT
RBC Initiates Pyxis Oncology at Outperform With Speculative Risk, Sets Price Target at $7, Sees 'Favorable' Risk/Reward	05/09/23	MT
Pyxis Oncology Completes Acquisition of Apexigen	23/08/23	MT
Pyxis Oncology, Inc. Appoints Jakob Dupont as Independent Director to the Board of Directors	23/08/23	CI
Pyxis Oncology, Inc. completed the acquisition of Apexigen, Inc. from entities associated with Pfizer Inc., Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.	22/08/23	CI
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Pyxis Oncology Doses First Subject in Phase 1 Trial of Immunotherapy Antibody Candidate	30/05/23	MT
Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs	30/05/23	CI
Wall Street Set to Open Lower as Investors Await Progress on Debt-Ceiling Talks Ahead of Fed Minutes Release	24/05/23	MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday	24/05/23	MT

Chart Pyxis Oncology, Inc.

Duration

Period

More charts

Company Profile

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.94 USD

Average target price

8.8 USD

Spread / Average Target

+199.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PYXIS ONCOLOGY, INC.	+63.33%	173M
VERTEX PHARMACEUTICALS INCORPORATED	+16.44%	122B
REGENERON PHARMACEUTICALS, INC.	+18.94%	113B
ARGENX SE	+19.62%	26.22B
BIONTECH SE	-25.37%	19.01B
GENMAB A/S	-20.21%	15.71B
BEIGENE, LTD.	-20.20%	15.22B
WUXI APPTEC CO., LTD.	-47.37%	14.72B
SAREPTA THERAPEUTICS, INC.	+59.91%	14.58B
NEUROCRINE BIOSCIENCES, INC.	+4.35%	13.84B

Bio Therapeutic Drugs